BACKGROUND: Ribonucleotide reductase catalyzes an essential step in the cellular production of deoxyribonucleotide triphosphates and has been associated with clinical outcome in cancer patients receiving nucleoside analog-based chemotherapy. MATERIALS & METHODS: In the current study, we sequenced the genes RRM1 and RRM2 in genomic DNA from HapMap cell lines with European (Utah residents with northern and western European ancestry [CEU]; n = 90) or African (Yoruba people in Ibadan, Nigeria [YRI]; n = 90) ancestry. RESULTS: We identified 44 genetic variants including eight coding SNPs in RRM1 and 15 SNPs including one coding SNP in RRM2. RRM1 and RRM2 mRNA expression levels were significantly correlated with each other in both CEU and YRI lymphoblast cell lines, and in leukemic blasts from acute myeloid leukemia (AML) patients (AML97, n = 89; AML02, n = 187). Additionally, RRM1 expression was higher among patient features indicative of a high relapse hazard. We evaluated SNPs within the RRM1 and RRM2 genes in the HapMap lymphoblast cell lines from CEU and YRI panels for association with expression and cytarabine chemosensitivity. SNPs of potential significance were further evaluated in AML patients. RRM1 SNPs rs1042919 (which occurs in linkage disequilbrium with multiple other SNPs) and promoter SNP rs1561876 were associated with intracellular 1-β-D-arabinofuranosyl-CTP levels, response after remission induction therapy, risk of relapse and overall survival in AML patients receiving cytarabine and cladribine. CONCLUSION: These results suggest that SNPs within ribonucleotide reductase might be helpful predictive markers of response to nucleoside analogs and should be further validated in larger cohorts.
BACKGROUND: Ribonucleotide reductase catalyzes an essential step in the cellular production of deoxyribonucleotide triphosphates and has been associated with clinical outcome in cancerpatients receiving nucleoside analog-based chemotherapy. MATERIALS & METHODS: In the current study, we sequenced the genes RRM1 and RRM2 in genomic DNA from HapMap cell lines with European (Utah residents with northern and western European ancestry [CEU]; n = 90) or African (Yoruba people in Ibadan, Nigeria [YRI]; n = 90) ancestry. RESULTS: We identified 44 genetic variants including eight coding SNPs in RRM1 and 15 SNPs including one coding SNP in RRM2. RRM1 and RRM2 mRNA expression levels were significantly correlated with each other in both CEU and YRI lymphoblast cell lines, and in leukemic blasts from acute myeloid leukemia (AML) patients (AML97, n = 89; AML02, n = 187). Additionally, RRM1 expression was higher among patient features indicative of a high relapse hazard. We evaluated SNPs within the RRM1 and RRM2 genes in the HapMap lymphoblast cell lines from CEU and YRI panels for association with expression and cytarabine chemosensitivity. SNPs of potential significance were further evaluated in AMLpatients. RRM1 SNPs rs1042919 (which occurs in linkage disequilbrium with multiple other SNPs) and promoter SNP rs1561876 were associated with intracellular 1-β-D-arabinofuranosyl-CTP levels, response after remission induction therapy, risk of relapse and overall survival in AMLpatients receiving cytarabine and cladribine. CONCLUSION: These results suggest that SNPs within ribonucleotide reductase might be helpful predictive markers of response to nucleoside analogs and should be further validated in larger cohorts.
Authors: Kristine R Crews; Varsha Gandhi; Deo Kumar Srivastava; Bassem I Razzouk; Xin Tong; Fred G Behm; William Plunkett; Susana C Raimondi; Ching-Hon Pui; Jeffrey E Rubnitz; Clinton F Stewart; Raul C Ribeiro Journal: J Clin Oncol Date: 2002-10-15 Impact factor: 44.544
Authors: Christine M Hartford; Shiwei Duan; Shannon M Delaney; Shuangli Mi; Emily O Kistner; Jatinder K Lamba; R Stephanie Huang; M Eileen Dolan Journal: Blood Date: 2008-12-24 Impact factor: 22.113
Authors: J E Rubnitz; K R Crews; S Pounds; S Yang; D Campana; V V Gandhi; S C Raimondi; J R Downing; B I Razzouk; C-H Pui; R C Ribeiro Journal: Leukemia Date: 2009-02-26 Impact factor: 11.528
Authors: Ting Deng; Hong Pan; Rubing Han; Dingzhi Huang; Hongli Li; Likun Zhou; Xia Wang; Ming Bai; Xiang Li; Rui Liu; Shaohua Ge; Tao Ning; Le Zhang; Yi Ba Journal: Int J Clin Exp Med Date: 2014-12-15
Authors: Abdelrahman H Elsayed; Xueyuan Cao; Amit K Mitra; Huiyun Wu; Susana Raimondi; Christopher Cogle; Zeina Al-Mansour; Raul C Ribeiro; Alan Gamis; Edward Anders Kolb; Richard Aplenc; Todd A Alonzo; Soheil Meshinchi; Jeffrey Rubnitz; Stanley Pounds; Jatinder K Lamba Journal: J Clin Oncol Date: 2022-01-06 Impact factor: 50.717
Authors: Abdelrahman H Elsayed; Xueyuan Cao; Kristine R Crews; Varsha Gandhi; William Plunkett; Jeffrey E Rubnitz; Raul C Ribeiro; Stanley B Pounds; Jatinder K Lamba Journal: Pharmacogenomics Date: 2018-08-08 Impact factor: 2.533
Authors: María José Zarzuelo Romero; Cristina Pérez Ramírez; María Isabel Carrasco Campos; Almudena Sánchez Martín; Miguel Ángel Calleja Hernández; María Carmen Ramírez Tortosa; Alberto Jiménez Morales Journal: J Pers Med Date: 2021-04-23
Authors: Neha S Bhise; Lata Chauhan; Miyoung Shin; Xueyuan Cao; Stanley Pounds; Vishal Lamba; Jatinder K Lamba Journal: Front Pharmacol Date: 2016-01-28 Impact factor: 5.810